felbamate	Valproate	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	40254	none	40254
felbamate	Valproate	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	40254	none	40254
felbamate	Valproate	3	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	40254	none	40254
felbamate	Valproate	3	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	40254	none	40254
felbamate	Valproate	3	4	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	40254	none	40254
felbamate	Valproate	3	4	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	40254	none	40254
felbamate	Valproate	3	5	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	40254	none	40254
felbamate	Valproate	3	5	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	40254	none	40254
felbamate	Valproate	4	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	40254	none	40254
felbamate	Valproate	4	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	40254	none	40254
felbamate	Valproate	4	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	40254	none	40254
felbamate	Valproate	4	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	40254	none	40254
felbamate	Valproate	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	40254	none	40254
felbamate	Valproate	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	40254	none	40254
felbamate	Valproate	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		none	40254	none	40254
felbamate	Valproate	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		none	40254	none	40254
felbamate	Felbatol	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	0	none	224900
felbamate	Felbatol	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	0	none	224900
felbamate	Felbatol	3	5	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	0	none	224900
felbamate	Felbatol	3	5	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	0	none	224900
felbamate	Felbatol	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	0	none	224900
felbamate	Felbatol	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	0	none	224900
felbamate	Felbatol	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		none	0	none	224900
felbamate	Felbatol	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		none	0	none	224900
felbamate	valproate	3	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	none	none	none
felbamate	valproate	3	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  		none	none	none	none
felbamate	valproate	3	4	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	none	none	none
felbamate	valproate	3	5	true	positive	The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	none	none	none
felbamate	valproate	4	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	none	none	none
felbamate	valproate	4	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		none	none	none	none
felbamate	valproate	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		none	none	none	none
felbamate	valproate	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		none	none	none	none
Valproate	Felbatol	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  		40254	0	40254	224900
Valproate	Felbatol	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  		40254	0	40254	224900
Valproate	Felbatol	2	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	0	40254	224900
Valproate	Felbatol	2	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	0	40254	224900
Valproate	Felbatol	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	5	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	5	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	5	6	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	5	6	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	5	7	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	5	7	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	6	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	6	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	6	6	false	none	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	6	6	false	none	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	0	40254	224900
Valproate	Felbatol	6	7	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	6	7	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	7	5	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	7	5	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	7	6	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	7	6	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	7	7	true	negative	This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	Felbatol	7	7	true	negative	This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	0	40254	224900
Valproate	valproate	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  		40254	none	40254	none
Valproate	valproate	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  		40254	none	40254	none
Valproate	valproate	1	2	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	1	2	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	2	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	2	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	2	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	2	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	2	4	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	2	4	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	4	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	4	2	true	positive	In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  The steady-state Cmin increased to 78±14 micrograms/mL when 1200 mg/day of felbamate was coadministered.  Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	4	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	4	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  		40254	none	40254	none
Valproate	valproate	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	4	5	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	4	6	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	6	true	positive	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	6	true	positive	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	5	7	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	5	7	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	6	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	6	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	6	5	true	positive	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	6	5	true	positive	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	6	6	true	positive	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	6	6	true	positive	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		40254	none	40254	none
Valproate	valproate	6	7	true	positive	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	6	7	true	positive	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	7	5	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	7	5	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	7	6	true	positive	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	7	6	true	positive	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	7	7	true	negative	This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Valproate	valproate	7	7	true	negative	This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		40254	none	40254	none
Felbatol	valproate	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  		0	none	224900	none
Felbatol	valproate	1	1	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  		0	none	224900	none
Felbatol	valproate	1	2	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		0	none	224900	none
Felbatol	valproate	1	2	true	positive	Valproate: Felbatol® causes an increase in steady-state valproate concentrations.  In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63±16 micrograms/mL.  		0	none	224900	none
Felbatol	valproate	5	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	5	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	5	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	5	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	5	6	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	5	6	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	5	7	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	5	7	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	6	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	6	4	true	positive	Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 96±25 micrograms/mL.  Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	6	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	6	5	false	none	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	6	6	false	none	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	6	6	false	none	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  		0	none	224900	none
Felbatol	valproate	6	7	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	6	7	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	7	5	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	7	5	true	negative	Corresponding values for free valproate Cmin concentrations were 7±3, 9±4, and 11±6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol®, respectively.  The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	7	6	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	7	6	true	negative	The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol®, respectively.  This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	7	7	true	negative	This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
Felbatol	valproate	7	7	true	negative	This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol®.  		0	none	224900	none
